We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Mao Rong Reed Smith LLP

Results 1 to 5 of 17



Approval from the State Food and Drug Administration concerning drug registration and appraisal reform on pilot basis in Guangdong Food and Drug Administration *

China - December 12 2012
State Food and Drug Administration (SFDA) indicated November 2 that it approved Guangdong Province to assume drug evaluation and approval responsibilities on a pilot basis.

Co-authors: John Tan, Jay J. Yan, Katherine Yang, May Ling Wong, Hugh Scogin.


MOH issues action plan on hospital infections *

China - November 16 2012
The Ministry of Health (MOH) released the Action Plan for Preventing and Controlling Hospital (Nosocomial) Infections (2012- 2015).

Co-authors: John Tan, Jay J. Yan, Katherine Yang, May Ling Wong, Hugh Scogin.


State Council issues the 12th FYP for public health services development *

China - November 16 2012
On October 19, the State Council issued the 12th Five-Year Plan for the development of public health services.

Co-authors: John Tan, Jay J. Yan, Katherine Yang, May Ling Wong, Hugh Scogin.


Life sciences health industry China briefing - June 2012 (July 20, 2012) *

China - July 20 2012
China's new patent regulations allowing the government to force drug companies to grant compulsory licenses for generic versions of their products if it is deemed to be in the "public interest" has the pharmaceutical industry worried about where China will draw the line, attorneys said.

Co-authors: John Tan, Jay J. Yan, Katherine Yang, Gordon B. Schatz.


Life sciences health industry China briefing *

China - July 20 2012
China's new patent regulations allowing the government to force drug companies to grant compulsory licenses for generic versions of their products if it is deemed to be in the "public interest" has the pharmaceutical industry worried about where China will draw the line, attorneys said.

Co-authors: John Tan, Jay J. Yan, Katherine Yang, Gordon B. Schatz.


Next »